DexCom Inc (DXCM) stock
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3031% below fair value
$82.04+0.43 (+0.53%)
Close on Nov 17, 2026Market cap $30.60BP/E 32.3Yield –
DexCom r&d expenses
Research and development expenses are spending on new products and technology.
DexCom's R&D Expenses for the twelve months ending Sep 30, 2026 was $608.10M, up 3.0% year over year. For fiscal 2025 it was $599.10M, up 8.5% from the year before. Over ten years it grew 15.9% a year on average. The highest annual figure on record is $599.10M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $599.10M | +8.5% |
| FY2024 | Dec 31, 2024 | $552.40M | +9.2% |
| FY2023 | Dec 31, 2023 | $505.80M | +4.5% |
| FY2022 | Dec 31, 2022 | $484.20M | -6.4% |
| FY2021 | Dec 31, 2021 | $517.10M | +43.7% |
| FY2020 | Dec 31, 2020 | $359.90M | +31.6% |
| FY2019 | Dec 31, 2019 | $273.50M | +37.0% |
| FY2018 | Dec 31, 2018 | $199.70M | +7.7% |
| FY2017 | Dec 31, 2017 | $185.40M | +18.8% |
| FY2016 | Dec 31, 2016 | $156.10M | +13.5% |
| FY2015 | Dec 31, 2015 | $137.50M | +98.1% |
| FY2014 | Dec 31, 2014 | $69.40M | +54.9% |
| FY2013 | Dec 31, 2013 | $44.80M | +17.0% |
| FY2012 | Dec 31, 2012 | $38.30M | +29.4% |
| FY2011 | Dec 31, 2011 | $29.60M | +27.6% |
| FY2010 | Dec 31, 2010 | $23.20M | +62.3% |
| FY2009 | Dec 31, 2009 | $14.29M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $161.60M | +2.6% |
| Q2 FY2026 | Jun 30, 2026 | $153.00M | +3.2% |
| Q1 FY2026 | Mar 31, 2026 | $145.30M | +0.1% |
| Q4 FY2025 | Dec 31, 2025 | $148.20M | +6.2% |
| Q3 FY2025 | Sep 30, 2025 | $157.50M | +16.3% |
| Q2 FY2025 | Jun 30, 2025 | $148.20M | +9.0% |
| Q1 FY2025 | Mar 31, 2025 | $145.20M | +2.6% |
| Q4 FY2024 | Dec 31, 2024 | $139.50M | +2.5% |
| Q3 FY2024 | Sep 30, 2024 | $135.40M | +3.0% |
| Q2 FY2024 | Jun 30, 2024 | $136.00M | +14.0% |
| Q1 FY2024 | Mar 31, 2024 | $141.50M | +18.9% |
| Q4 FY2023 | Dec 31, 2023 | $136.10M | +17.0% |
| Q3 FY2023 | Sep 30, 2023 | $131.40M | +19.1% |
| Q2 FY2023 | Jun 30, 2023 | $119.30M | -2.0% |
| Q1 FY2023 | Mar 31, 2023 | $119.00M | -12.4% |
| Q4 FY2022 | Dec 31, 2022 | $116.30M | -22.4% |
| Q3 FY2022 | Sep 30, 2022 | $110.30M | -14.4% |
| Q2 FY2022 | Jun 30, 2022 | $121.70M | -5.7% |
| Q1 FY2022 | Mar 31, 2022 | $135.90M | +24.2% |
| Q4 FY2021 | Dec 31, 2021 | $149.80M | +25.7% |
| Q3 FY2021 | Sep 30, 2021 | $128.80M | +46.9% |
| Q2 FY2021 | Jun 30, 2021 | $129.10M | +61.6% |
| Q1 FY2021 | Mar 31, 2021 | $109.40M | +49.7% |
| Q4 FY2020 | Dec 31, 2020 | $119.20M | +51.3% |
| Q3 FY2020 | Sep 30, 2020 | $87.70M | +31.5% |
| Q2 FY2020 | Jun 30, 2020 | $79.90M | +15.8% |
| Q1 FY2020 | Mar 31, 2020 | $73.10M | +23.9% |
| Q4 FY2019 | Dec 31, 2019 | $78.80M | +36.8% |
| Q3 FY2019 | Sep 30, 2019 | $66.70M | +33.1% |
| Q2 FY2019 | Jun 30, 2019 | $69.00M | +46.2% |
| Q1 FY2019 | Mar 31, 2019 | $59.00M | +31.7% |
| Q4 FY2018 | Dec 31, 2018 | $57.60M | +18.3% |
| Q3 FY2018 | Sep 30, 2018 | $50.10M | +15.7% |
| Q2 FY2018 | Jun 30, 2018 | $47.20M | +4.2% |
| Q1 FY2018 | Mar 31, 2018 | $44.80M | -6.9% |
| Q4 FY2017 | Dec 31, 2017 | $48.70M | +11.4% |
| Q3 FY2017 | Sep 30, 2017 | $43.30M | – |
| Q2 FY2017 | Jun 30, 2017 | $45.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $48.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $43.70M | – |
See a number that looks wrong?